`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED
`Patent Owner.
`
`_____________________________
`
`
`
`Case IPR2022-00722
`Patent 7,041,786
`_____________________________
`
`PETITIONER MYLAN PHARMACEUTICALS INC.’S
`MANDATORY CHANGE-OF-INFORMATION NOTICES
`37 C.F.R. § 42.8(a)(3)
`
`
`
`Case IPR2022-00722
`U.S. Patent 7,041,786
`
`Petitioner Mylan Pharmaceuticals Inc. (Mylan) submits the following
`
`mandatory change-of-information notices for IPR2022-00722.
`
`A.
`
`Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Revised
`
`Petitioner Mylan Pharmaceuticals Inc. is a co-defendant with Mylan
`
`Laboratories Ltd., Agila Specialties Inc, Mylan API US LLC, Mylan Inc., and Viatris
`
`Inc. in parallel litigation. Additionally, Viatris Inc. and Mylan Inc. are parent
`
`companies of Mylan Pharmaceuticals Inc.
`
`B.
`
`Related Matters (37 C.F.R. § 42.8(b)(2)) – Revised
`
`Bausch asserted the involved patent in Bausch Health Ireland Ltd. v. Mylan
`
`Laboratories Ltd., 2:21-cv-573 (WDPA) (administratively closed); 1:22-cv-00020-
`
`TSK (NDWV) (5-day trial set for June 17, 2024); and in Bausch Health Ireland Ltd.
`
`v. MSN Labs., 2:21-cv-10057-SRC (DNJ) (third-party litigation: Mylan is not
`
`involved; no trial date set).
`
`IPR2022-01102, IPR2022-01103, IPR2022-01104, and IPR2022-01105
`
`involve later patents related to the challenged patent.
`
`-2-
`
`
`
`Case IPR2022-00722
`U.S. Patent 7,041,786
`
`C.
`
`Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Unchanged
`
`Lead Counsel
`Jad Mills. No. 63,334
`WILSON SONSINI GOODRICH &
`ROSATI
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104
`Tel.: 206-883-2554 Fax: 206-883-2699
`Email: jmills@wsgr.com
`
`Nicole Stafford No. 43,929
`WILSON SONSINI GOODRICH &
`ROSATI
`900 South Capital of Texas Highway
`Las Cimas IV, Fifth Floor
`Austin, TX 78746-5546
`Tel.: 512-338-5402 Fax: 512-338-5499
`Email: nstafford@wsgr.com
`
`First Back-Up Counsel
`Richard Torczon, Reg. No. 34,448
`WILSON SONSINI GOODRICH &
`ROSATI
`1700 K Street N.W., 5th Floor,
`Washington, DC 20006-3817
`Tel.: 202-973-8811 Fax: 202-973-8899
`Email: rtorczon@wsgr.com
`Back-Up Counsel
`Denis Gregory, Reg. No. 52,967
`WILSON SONSINI GOODRICH &
`ROSATI
`900 South Capital of Texas Highway
`Las Cimas IV, Fifth Floor
`Austin, TX 78746-5546
`Tel.: 512-338-5426 Fax: 512-338-5499
`Email: dgregory@wsgr.com
`
`D.
`
`Electronic Service
`
`Petitioner consents to electronic service by email at the email addresses provided
`
`above and 4863-5899-2145@mail.vault.netdocuments.com.
`
`Date: July 11, 2022
`
`Respectfully submitted,
`
`/Richard Torczon/
`Richard Torczon, Reg. No. 34,448
`Counsel for Mylan Pharmaceuticals, Inc.
`
`-3-
`
`
`
`Case IPR2022-00722
`U.S. Patent 7,041,786
`
`CERTIFICATE OF SERVICE
`
`I certify that today this paper was served on the Patent Owner at the Patent Owner’s
`
`email correspondence addresses as follows:
`
`Justin J. Hasford
`
`Bryan C. Diner
`
`justin.hasford@finnegan.com
`
`bryan.diner@finnegan.com
`
`Date: July 11, 2022
`
`Respectfully submitted,
`
`/Robyn Moriarty/
`Robyn Moriarty
`
`-4-
`
`